175 related articles for article (PubMed ID: 22939808)
1. Haptoglobin genotype and cardiovascular outcomes in diabetes mellitus - natural history of the disease and the effect of vitamin E treatment. Meta-analysis of the medical literature.
Vardi M; Blum S; Levy AP
Eur J Intern Med; 2012 Oct; 23(7):628-32. PubMed ID: 22939808
[TBL] [Abstract][Full Text] [Related]
2. Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype.
Blum S; Vardi M; Brown JB; Russell A; Milman U; Shapira C; Levy NS; Miller-Lotan R; Asleh R; Levy AP
Pharmacogenomics; 2010 May; 11(5):675-84. PubMed ID: 20415560
[TBL] [Abstract][Full Text] [Related]
3. Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial.
Milman U; Blum S; Shapira C; Aronson D; Miller-Lotan R; Anbinder Y; Alshiek J; Bennett L; Kostenko M; Landau M; Keidar S; Levy Y; Khemlin A; Radan A; Levy AP
Arterioscler Thromb Vasc Biol; 2008 Feb; 28(2):341-7. PubMed ID: 18032779
[TBL] [Abstract][Full Text] [Related]
4. Patient selection and vitamin E treatment in diabetes mellitus.
Goldenstein H; Levy NS; Lipener YT; Levy AP
Expert Rev Cardiovasc Ther; 2013 Mar; 11(3):319-26. PubMed ID: 23469912
[TBL] [Abstract][Full Text] [Related]
5. Is it time to screen for the haptoglobin genotype to assess the cardiovascular risk profile and vitamin E therapy responsiveness in patients with diabetes?
Vardi M; Levy AP
Curr Diab Rep; 2012 Jun; 12(3):274-9. PubMed ID: 22427005
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomic application of the haptoglobin genotype in the prevention of diabetic cardiovascular disease.
Blum S; Milman U; Shapira C; Levy AP
Pharmacogenomics; 2008 Aug; 9(8):989-91. PubMed ID: 18681772
[No Abstract] [Full Text] [Related]
7. Interaction Between the Haptoglobin Genotype and Vitamin E on Cardiovascular Disease in Diabetes.
Hochberg I; Berinstein EM; Milman U; Shapira C; Levy AP
Curr Diab Rep; 2017 Jun; 17(6):42. PubMed ID: 28451949
[TBL] [Abstract][Full Text] [Related]
8. Haptoglobin: a major susceptibility gene for diabetic cardiovascular disease.
Levy AP
Isr Med Assoc J; 2004 May; 6(5):308-10. PubMed ID: 15151377
[No Abstract] [Full Text] [Related]
9. Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype.
Asleh R; Blum S; Kalet-Litman S; Alshiek J; Miller-Lotan R; Asaf R; Rock W; Aviram M; Milman U; Shapira C; Abassi Z; Levy AP
Diabetes; 2008 Oct; 57(10):2794-800. PubMed ID: 18599520
[TBL] [Abstract][Full Text] [Related]
10. The protean role of haptoglobin and haptoglobin genotypes on vascular complications in diabetes mellitus.
Dalan R; Liuh Ling G
Eur J Prev Cardiol; 2018 Sep; 25(14):1502-1519. PubMed ID: 29799294
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenomics in prevention of diabetic cardiovascular disease: utilization of the haptoglobin genotype in determining benefit from vitamin E.
Levy AP; Blum S
Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1105-11. PubMed ID: 18035926
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of the association of the haptoglobin genotype with cardiovascular outcomes and the pharmacogenomic interactions with vitamin E supplementation.
Asleh R; Briasoulis A; Berinstein EM; Wiener JB; Palla M; Kushwaha SS; Levy AP
Pharmgenomics Pers Med; 2018; 11():71-82. PubMed ID: 29731659
[TBL] [Abstract][Full Text] [Related]
13. The Role of Haptoglobin Polymorphism in Cardiovascular Disease in the Setting of Diabetes.
Somer S; Levy AP
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396615
[TBL] [Abstract][Full Text] [Related]
14. Anti-oxidative treatment with vitamin E improves peripheral vascular function in patients with diabetes mellitus and Haptoglobin 2-2 genotype: A double-blinded cross-over study.
Alshiek JA; Dayan L; Asleh R; Blum S; Levy AP; Jacob G
Diabetes Res Clin Pract; 2017 Sep; 131():200-207. PubMed ID: 28759833
[TBL] [Abstract][Full Text] [Related]
15. Vitamin E in the prevention of cardiovascular disease: the importance of proper patient selection.
Vardi M; Levy NS; Levy AP
J Lipid Res; 2013 Sep; 54(9):2307-14. PubMed ID: 23505320
[TBL] [Abstract][Full Text] [Related]
16. Effect of vitamin E supplementation on HDL function by haptoglobin genotype in type 1 diabetes: results from the HapE randomized crossover pilot trial.
Costacou T; Levy AP; Miller RG; Snell-Bergeon J; Asleh R; Farbstein D; Fickley CE; Pambianco G; de la Vega R; Evans RW; Orchard TJ
Acta Diabetol; 2016 Apr; 53(2):243-50. PubMed ID: 26002590
[TBL] [Abstract][Full Text] [Related]
17. Haptoglobin phenotype, pre-eclampsia, and response to supplementation with vitamins C and E in pregnant women with type-1 diabetes.
Weissgerber TL; Gandley RE; Roberts JM; Patterson CC; Holmes VA; Young IS; McCance DR;
BJOG; 2013 Sep; 120(10):1192-9. PubMed ID: 23718253
[TBL] [Abstract][Full Text] [Related]
18. Haptoglobin 2-2 genotype is not associated with cardiovascular risk in subjects with elevated glycohemoglobin-results from the Bruneck Study.
Pechlaner R; Kiechl S; Willeit P; Demetz E; Haun M; Weger S; Oberhollenzer F; Kronenberg F; Bonora E; Weiss G; Willeit J
J Am Heart Assoc; 2014 May; 3(3):e000732. PubMed ID: 24837587
[TBL] [Abstract][Full Text] [Related]
19. The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes.
Levy AP; Gerstein HC; Miller-Lotan R; Ratner R; McQueen M; Lonn E; Pogue J
Diabetes Care; 2004 Nov; 27(11):2767. PubMed ID: 15505023
[No Abstract] [Full Text] [Related]
20. Antioxidants in the prevention of atherosclerosis: the importance of proper patient selection.
Levy Y; Blum S; Levy AP
Clin Nutr; 2009 Oct; 28(5):581-2. PubMed ID: 19464773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
